Characterize the Immune-Oncologic Profile of Lethal Prostate Cancer in African American Men and Develop New Therapeutic Avenues for This Patient Population
Abstract
More African American men get and die from prostate cancer than European American men. They tend to get a more aggressive form of the disease. We know that genes play a role in these cancer health disparities. If we learn more about the role of genes, then we might be able to give better care to African American men with prostate cancer and save more lives. Currently, research to identify the reason why there are such extreme differences in prostate cancer between African American and European American men is scarce due to the limited amount of information specific to African American men with prostate cancer. Our group recently developed a large pool of information using prostate cancer tumor samples of African American and European American men from Moffitt Cancer Center and partner institutions. This large amount of new information will allow us to more carefully investigate the differences between African American men and European American men with prostate cancer using clinical information and outcomes, as well as information found directly within the prostate cancer tumor. The goal of this study is to identify these distinct differences of prostate cancer in African American and European American men, which will lead to more personalized care for African American men with prostate cancer. Successful completion of the outlined study will change the way that African American men with prostate cancer are treated within the near future (less than or equal to 3-5 years). We will look for markers in the tumor samples that could help us know when patients have an aggressive type of prostate cancer. This type of prostate cancer requires different treatment to the standard treatment given to most patients. If we find these markers, then it will help doctors give African American patients the right treatments. With this work, we will take important steps toward personalized medicine. This kind of medicine is tailored to the biology of the individual, making it more effective than a “one size fits all” approach. It can help overcome cancer health disparities.
Document Details
- Document Type
- DoD Grant Award
- Publication Date
- Nov 19, 2019
- Source ID
- W81XWH1910435
Entities
People
- Kosj Yamoah
Organizations
- H. Lee Moffitt Cancer Center & Research Institute
- United States Army